- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:54 | BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations | 46 | GlobeNewswire (Europe) | NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance... ► Artikel lesen | |
| 19.03. | Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector | 2 | FierceBiotech | ||
| 19.03. | BiomX CEO Issues Letter to Stockholders | 164 | PR Newswire | CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities
... ► Artikel lesen | |
| 19.03. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | BiomX appoints Michael Oster as CEO David Rokach as CFO | 2 | Seeking Alpha | ||
| 09.03. | H.C. Wainwright downgrades BiomX stock rating to neutral | 1 | Investing.com | ||
| 09.03. | H.C. Wainwright stuft BiomX-Aktie auf "Neutral" herab | 1 | Investing.com Deutsch | ||
| 09.03. | Biomx Ltd.: BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth | 146 | PR Newswire | Seasoned financial leaders join BiomX to support strategic execution and advancement of the company
DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/... ► Artikel lesen | |
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 09.03. | BiomX Names Michael Oster As CEO, David Rokach CFO | 3 | RTTNews | ||
| 09.03. | BiomX appoints Michael Oster CEO, David Rokach CFO | 1 | Investing.com | ||
| 06.03. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.02. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | BiomX Inc. - 10-K, Annual Report | 5 | SEC Filings | ||
| 10.02. | BiomX Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 27.01. | BiomX Inc: BiomX Issues Statement Regarding Recent Common Stock Trading Activity | 177 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 27.01. | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | 476 | AFX News | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 14.01. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 29.12.25 | BiomX Inc: BiomX Announces $3.0 Million Private Placement | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,65 | +0,13 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| AMGEN | 305,85 | -0,08 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| INOVIO PHARMACEUTICALS | 1,350 | +0,75 % | Inovio Q4 2025 slides: BLA accepted but FDA questions linger | ||
| DEFENCE THERAPEUTICS | 0,346 | -5,72 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,191 | -2,02 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| CARDIOL THERAPEUTICS | 0,916 | -1,51 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,860 | +2,26 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| KYNTRA BIO | 5,950 | +0,85 % | Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| ARMATA PHARMACEUTICALS | 7,100 | -10,13 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results | LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology... ► Artikel lesen | |
| VAXCYTE | 48,000 | 0,00 % | Vaxcyte, Inc.: Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults | OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 4,060 | +1,50 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | - YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 - - Company earned $35.6 million in total revenue... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics | NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,415 | -3,50 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate... ► Artikel lesen | |
| QIAGEN | 34,965 | +0,07 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,770 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.